Individuals can easily collect their saliva sample and send it to a laboratory for further processing. Credit: National Cancer Institute on Unsplash.

Grifols has introduced its direct-to-consumer programme, AlphaID At Home Genetic Health Risk Service (AlphaID At Home), in the US.

The new programme will help screen for the genetic risk of alpha1-antitrypsin deficiency (alpha-1), which is also called genetic chronic obstructive pulmonary disease.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In November 2022, the US Food and Drug Administration (FDA) approved AlphaID At Home for direct-to-consumer use.

The test can screen for the most prevalently reported genetic mutations linked to alpha-1, including the S, Z, F and I alleles, as well as rare and null alleles.

It utilises the same precise genotyping test manufactured by the company and provided to physicians worldwide since 2018 for alpha-1 screening.

Grifols Diagnostic president Antonio Martínez said: “Given the fact that it can take several years until a patient with alpha-1 is properly diagnosed, AlphaID At Home can indicate someone’s risk for alpha-1 in a matter of weeks.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

AlphaID At Home is now accessible for ordering in the US at no cost via a secure online portal that complies with HIPAA standards.

After receiving the at-home screening kit, individuals can easily collect their saliva sample and send it to a laboratory adhering to the Clinical Laboratory Improvement Amendments standards for further processing.

Individuals can access their genetic results through a secure online portal after a few weeks.

Alpha-1 Foundation president and CEO Scott Santarella said: “We wholeheartedly support initiatives and innovations that contribute to the diagnosis of alpha-1. As leaders in alpha-1 testing, Grifols is doubling down on its commitment to the alpha-1 community by making it easier and more efficient to get diagnosed.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact